{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:32:59Z","timestamp":1790695979441,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T00:00:00Z","timestamp":1398124800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1038\/bjc.2014.195","type":"journal-article","created":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T20:32:07Z","timestamp":1398198727000},"page":"2434-2440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies"],"prefix":"10.1038","volume":"110","author":[{"given":"C-C","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W-C","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C-J","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C-H","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W-P","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K-H","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-S","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-L","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D C-L","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Taube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C-H","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,22]]},"reference":[{"issue":"15_suppl","key":"BFbjc2014195_CR1","doi-asserted-by":"publisher","first-page":"abstract 3012","DOI":"10.1200\/jco.2011.29.15_suppl.3012","volume":"29","author":"T Doi","year":"2011","unstructured":"Doi T, Murakami H, Wan K, Miki M, Kotani H, Sakamoto N, Yamamoto N, Okano Y (2011) A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 29 (15_suppl): abstract 3012.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014195_CR2","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.3747\/co.19.866","volume":"19","author":"A Frost","year":"2012","unstructured":"Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, Trommeshauser D, Munzert G (2012) Phase I study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol 19: e28\u2013e35.","journal-title":"Curr Oncol"},{"key":"BFbjc2014195_CR3","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-06-0214","volume":"12","author":"LL Garland","year":"2006","unstructured":"Garland LL, Taylor C, Pilkington DL, Cohen JL, Von Hoff DD (2006) A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res 12: 5182\u20135189.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014195_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1158\/1535-7163.MCT-11-0762","volume":"11","author":"Y Hikichi","year":"2012","unstructured":"Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S, Uchiyama N, Hasegawa M, Kawamoto T, Sato T, Ichikawa T, Cao S, Nie Z, Zhang L, Yang J, Kuida K, Kupperman E (2012) TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther 11: 700\u2013709.","journal-title":"Mol Cancer Ther"},{"key":"BFbjc2014195_CR5","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.1158\/1078-0432.CCR-10-0318","volume":"16","author":"RD Hofheinz","year":"2010","unstructured":"Hofheinz RD, Al-Batran SE, Hochhaus A, J\u00e4ger E, Reichardt VL, Fritsch H, Trommeshauser D, Munzert G (2010) An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 16: 4666\u20134674.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014195_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1177\/009286150203600415","volume":"36","author":"SH Kang","year":"2002","unstructured":"Kang SH, Ahn CW (2002) An investigation of the traditional algorithm-based designs for Phase 1 cancer trials. Drug Inf J 36: 865\u2013873.","journal-title":"Drug Inf J"},{"key":"BFbjc2014195_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Amer Statist Assoc 53: 457\u2013481.","journal-title":"J Amer Statist Assoc"},{"key":"BFbjc2014195_CR8","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.1073\/pnas.1031523100","volume":"100","author":"X Liu","year":"2003","unstructured":"Liu X, Erikson RL (2003) Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 100: 5789\u20135794.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc2014195_CR9","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1158\/1078-0432.CCR-11-0541","volume":"17","author":"RH Medema","year":"2011","unstructured":"Medema RH, Lin CC, Yang JC (2011) Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res 17: 6459\u20136466.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014195_CR10","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1200\/JCO.2008.16.1547","volume":"26","author":"K Mross","year":"2008","unstructured":"Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Rouyrre N, Trommeshauser D, Hoesl CE, Munzert G (2008) Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 26: 5511\u20135517.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014195_CR11","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-10-2946","volume":"17","author":"D Olmos","year":"2011","unstructured":"Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, de Bono JS, Blagden SP (2011) Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 17: 3420\u20133430.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014195_CR12","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","volume":"15","author":"D Rudolph","year":"2009","unstructured":"Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR (2009) BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15: 3094\u20133102.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014195_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejca.2011.11.001","volume":"48","author":"P Sch\u00f6ffski","year":"2012","unstructured":"Sch\u00f6ffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G (2012) A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 48: 179\u2013186.","journal-title":"Eur J Cancer"},{"key":"BFbjc2014195_CR14","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/jnci\/94.24.1863","volume":"94","author":"B Spankuch-Schmitt","year":"2002","unstructured":"Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K (2002) Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94: 1863\u20131877.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2014195_CR15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/cncr.28519","volume":"120","author":"WM Stadler","year":"2014","unstructured":"Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen P, Lin C-C, Mahoney J, Modi S, Lee P, Ernstoff MS, Su W-C, Spira A, Pilz K, Vinisko R, Schloss C, Fritsch H, Zhao C, Carducci MA (2014) An open-label, single-arm phase II trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer 120: 976\u2013982.","journal-title":"Cancer"},{"key":"BFbjc2014195_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrd3184","volume":"9","author":"K Strebhardt","year":"2010","unstructured":"Strebhardt K (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9: 643\u2013660.","journal-title":"Nat Rev Drug Discov"},{"key":"BFbjc2014195_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1349-7006.2003.tb01411.x","volume":"94","author":"T Takahashi","year":"2003","unstructured":"Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S (2003) Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 94: 148\u2013152.","journal-title":"Cancer Sci"},{"key":"BFbjc2014195_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205\u2013216.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2014195_CR19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/1535-7163.MCT-11-0765","volume":"11","author":"B Valsasina","year":"2012","unstructured":"Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J (2012) NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther 11: 1006\u20131016.","journal-title":"Mol Cancer Ther"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2014195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014195","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:22:47Z","timestamp":1684416167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2014195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,22]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["BFbjc2014195"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2014.195","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,22]]},"assertion":[{"value":"27 November 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A-LC: Honoraria from speakers bureau, Bayer Taiwan Co., Ltd, and consultant\/advisory board Eisai Inc. and Excelixis Inc. DC-LH, HF, FV, and TT: employment, Boehringer Ingelheim. JC-HY: provided uncompensated expert testimony to afatinib produced by Boehringer Ingelheim in Taiwan FDA. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}